Tebentafusp + Tebentafusp with Pembrolizumab + Investigators Choice
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Melanoma
Conditions
Advanced Melanoma
Trial Timeline
Dec 19, 2022 → Jul 1, 2028
NCT ID
NCT05549297About Tebentafusp + Tebentafusp with Pembrolizumab + Investigators Choice
Tebentafusp + Tebentafusp with Pembrolizumab + Investigators Choice is a phase 3 stage product being developed by Immunocore for Advanced Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05549297. Target conditions include Advanced Melanoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Melanoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05549297 | Phase 3 | Recruiting |
Competing Products
20 competing products in Advanced Melanoma